American Academy of Neurology Annual Meeting (AAN)

Karen Lynch, MD, MRCPI, senior global medical director at Sanofi, discussed ongoing unmet needs in CIDP, diagnostic challenges, and emerging research efforts evaluating complement inhibition and biomarker-driven care approaches.

Anup Patel, MD, pediatric epileptologist at Nationwide Children’s Hospital and leader within the Pediatric Epilepsy Research Consortium, discusses evolving AI-driven initiatives, Lennox-Gastaut syndrome research priorities, and future directions in pediatric epilepsy care.

A retrospective study presented at AAN 2026 suggested that short-course methylprednisolone tapers may reduce headache severity and daily headache burden in patients with acute posttraumatic headache after mild traumatic brain injury.

The assistant professor of neurology and ophthalmology at NYU Grossman School of Medicine discussed findings presented at AAN 2026 on the use of optical coherence tomography in pediatric MS. [WATCH TIME: 8 minutes]

Karen Lynch, MD, MRCPI, senior global medical director at Sanofi, discusses how delayed diagnosis in CIDP can contribute to irreversible nerve damage, long-term disability, and reduced functional recovery. [WATCH TIME: 3 minutes]

At AAN 2026, the professor of neurology at the University of South Florida discussed findings from the phase 3 NIMBLE trial assessing cemdisiran in generalized myasthenia gravis. [WATCH TIME: 5 minutes]

The professor of neurology and director of the Division of Movement Disorders at the University of Alabama at Birmingham discussed 3-year data on AMT-130 and its potential as a disease-modifying gene therapy for Huntington disease. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Scott Grossman, MD. [LISTEN TIME: 13 minutes]

Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.

H. E. Hinson, MD, MCR, FAAN, discussed how neurology is rapidly evolving toward interventional therapies, prevention-focused care, and adaptive trial designs, based on presentations from AAN 2026.

Kinan Muhammed, MD, PhD, consultant neurologist and co-founder and Chief Medical Officer for Kneu Health, discussed how smartphone-based remote monitoring tools may help clinicians track motor and cognitive changes in Parkinson disease and dementia more continuously.

The director of the Center for Neurological Restoration at Cleveland Clinic commented on tavapadon’s D1-selective mechanism, clinical development, and potential role in treating Parkinson disease across stages. [WATCH TIME: 4 minutes]

Bill Nye, science educator and advocate, reflects on Friedreich ataxia awareness, diagnostic challenges, and the evolving role of genetics and communication in advancing care.

Srikanth Muppidi, MD, a clinical professor of adult neurology at Stanford University, discussed phase 2 findings from the KYSA-6 trial of mivocabtagene autoleucel (miv-cel; KYV-101) in MG.

Amanda Piquet, MD, FAAN, spoke about data she presented at AAN's 2026 Meeting.

Following his symposium at the 2026 AAN Annual Meeting, science educator Bill Nye discussed his connection to Friedreich ataxia, emphasizing the importance of awareness, early diagnosis, and effective communication between clinicians and patients. [WATCH TIME: 4 minutes]

The associate chief quality officer at Nationwide Children’s Hospital discussed how AI-driven research initiatives within PERC are helping identify missed epilepsy diagnoses and improve care pathways in pediatric populations. [WATCH TIME: 3 minutes]

Neurologist Michael Levy, MD, PhD, outlines phase 3 METEOROID findings demonstrating satralizumab’s ability to reduce relapse risk and provide early, sustained disease control in patients with MOGAD.

The clinical professor of adult neurology at Stanford University discussed data he presented at AAN's 2026 Meeting [WATCH TIME: 4 minutes]

Amy Waldman, MD, associate professor of neurology at the Perelman School of Medicine at the University of Pennsylvania, breaks down phase 1–3 data showing zilganersen’s potential to modify disease progression in Alexander disease.

Phase 1 data presented at AAN 2026 suggest that investigational siRNA therapy RAG-17 may reduce key disease biomarkers and show early signs of clinical stabilization following a single dose in patients with SOD1-ALS.

The associate professor of neurology at the Perelman School of Medicine at the University of Pennsylvania discussed pivotal data on zilganersen, highlighting its efficacy, safety, and potential as the first disease-modifying therapy for Alexander disease.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed long-term TEMPO-4 data evaluating tavapadon’s impact on symptom control and levodopa utilization in Parkinson disease.

New long-term and post hoc data presented at the 2026 AAN Annual Meeting highlighted durable efficacy, safety, and patient-centered outcomes with nipocalimab in antibody-positive generalized myasthenia gravis.

Phase 3 data presented at AAN 2026 show that IVIG improves response rates in patients with autoimmune encephalitis refractory to steroids, supporting its role as a second-line immunotherapy option.

New pharmacokinetic data presented at AAN 2026 show that adolescents with focal epilepsy achieve cenobamate exposures comparable to adults, supporting simplified fixed-dose strategies and informing future pediatric development.

The director of the autoimmune neurology program at the University of Colorado discussed data she presented at AAN's 2026 Meeting [WATCH TIME: 5 minutes]

A national survey presented at AAN 2026 revealed significant gaps between patients with epilepsy and clinicians in seizure expectations, treatment decisions, and communication around risks like SUDEP.

The neurologist at the University of Oklahoma Medical Center highlighted early diagnosis, prevention of secondary injury, and multimodal monitoring as key to improving patient outcomes in TBI. [WATCH TIME: 5 minutes]

At AAN 2026, an associate professor of neurology at University of Washington discussed how delays in antiamyloid treatment initiation for early Alzheimer disease may be driven by real-world factors. [WATCH TIME: 5 minutes]